What Happened to Free Drug Interaction APIs? The 2024-2026 Landscape Shift

If you have searched for a free drug interaction API recently, you have probably noticed that the results are increasingly full of dead links, sunset notices, and deprecated documentation. This is not your imagination. The landscape of freely available, production-ready drug interaction APIs has contracted sharply between 2024 and 2026, leaving development teams with fewer options and harder trade-offs than at any point in the past decade.

Two years ago, a developer building a medication safety feature had a clear starting point: the NLM Drug Interaction API, a free government-maintained service that accepted RxCUI identifiers and returned structured interaction data with severity levels and source references. It was not perfect, but it was free, reasonably reliable, and backed by federal data infrastructure. That service no longer exists.

Understanding what happened, why it happened, and what remains available is essential for any team currently building or maintaining drug interaction checking capabilities. The decisions you make now will determine whether your interaction data pipeline is sustainable or built on the next service scheduled for retirement.

On January 2, 2024, the U.S. National Library of Medicine officially discontinued the RxNav Drug Interaction API. The API had been part of the RxNav family of services, providing drug-drug interaction data sourced from ONCHigh, a curated subset of clinical drug interactions maintained as part of the Office of the National Coordinator for Health IT's efforts.

NLM did not provide extensive public explanation for the discontinuation. The RxNav FAQ page confirmed the shutdown date and directed users to alternative resources, but the core message was clear: the federal government was exiting the business of providing a managed drug interaction checking API.

The impact was significant. The NLM Drug Interaction API was the only free, government-maintained API that returned structured interaction results with severity classifications. It accepted standard RxCUI identifiers, making it easy to integrate with systems already using RxNorm for drug normalization. Thousands of academic projects, clinical research tools, and small-scale healthcare applications relied on it as their primary interaction data source.

When the API went offline, those teams faced three options: migrate to a commercial API like DrugBank or First Databank, build a custom pipeline from raw FDA label data via openFDA, or remove drug interaction checking from their applications entirely. Each option carried significant cost, engineering effort, or capability loss.

Less than two years after the NLM shutdown, DrugBank announced the retirement of its free web-based Drug Interaction Checker, effective March 25, 2026. The checker, hosted at go.drugbank.com, allowed users to check interactions between up to five drugs at a time with basic severity information.

While the DrugBank checker was a web tool rather than a programmatic API, it served as a de facto free interaction reference for many development teams. Developers used it to validate their own interaction detection logic, QA teams used it to verify expected results, and some teams had built internal workflows around linking to checker results for specific drug pairs.

DrugBank's commercial API and embeddable DDI Checker plugin remain available as paid products, but the pricing represents a fundamentally different cost model than the free tool provided. For startups, academic projects, and small healthcare software companies, the gap between free and commercial pricing is often the gap between having interaction checking and not having it.

The DrugBank retirement is particularly notable because DrugBank itself published a blog post in 2024 covering the NLM API discontinuation, positioning their own tools as alternatives. The subsequent retirement of their free offering compounds the problem for teams that migrated to DrugBank after the NLM shutdown.

After the NLM and DrugBank shutdowns, the landscape of freely available drug interaction resources has narrowed considerably. Here is what still exists and what each option actually provides.

Before 2024, the calculation was simple: use the free NLM API for development and small-scale production, upgrade to a commercial API if you need higher volume or richer data. The NLM API served as a functional free tier for the entire drug interaction data market.

Without that free tier, teams face a binary choice. Either invest significant engineering effort in building a custom extraction pipeline from raw FDA label data, handling all the complexity of unstructured text parsing, drug name normalization, and severity classification yourself, or pay commercial rates for a managed solution.

Building from raw openFDA data is technically possible but substantially harder than calling a structured API. FDA label text is written in clinical narrative prose, not structured data. The same interaction might be described differently across labels from different manufacturers. Drug names appear in multiple forms: brand names, generic names, drug classes, and pharmacological categories. Extracting reliable interaction pairs with severity levels from this text requires natural language processing, clinical terminology mapping, and ongoing maintenance as labels are updated.

This engineering cost is the hidden tax of the free data path. The data itself is free, but transforming it into usable interaction results requires significant investment in extraction logic, normalization pipelines, and quality assurance processes.

The pattern of free drug interaction service shutdowns is not coincidental. Maintaining a drug interaction database is expensive. The data requires continuous curation as new drugs are approved, new interactions are discovered, and existing label text is updated. Quality assurance requires pharmacist review. Infrastructure requires ongoing operational investment.

Government agencies face budget constraints and shifting priorities. NLM's decision to discontinue the Drug Interaction API likely reflected a determination that maintaining a curated interaction database was outside its core mission of providing terminology and classification services. The RxNorm and RxNav services that remain operational align more closely with NLM's role as a medical terminology authority.

Commercial providers like DrugBank face market dynamics. Offering a free tool that cannibalized potential paying customers was a customer acquisition strategy that eventually reached its limits. As the company matured, the free checker became a cost center rather than a growth driver.

The practical implication is that free drug interaction APIs are unlikely to reappear from these providers. Any new free option will need to be built on a sustainable model, whether that is a venture-backed company using a freemium strategy, an open-source community project, or a service funded by API usage revenue at higher tiers.

If your application currently depends on a drug interaction data source, you need to verify that your source will still be available in twelve months. If it depends on the DrugBank free checker, you have already missed the deadline. If it depends on a commercial API, verify your contract terms and evaluate the pricing trajectory.

If you are building a new application that needs drug interaction checking, the most sustainable free path in 2026 is a managed API with a genuine free tier backed by a revenue model at higher usage levels. This is the model RxLabelGuard provides: free access for development and low-volume production, with paid tiers for higher usage that fund the infrastructure and data pipeline.

The raw data path via openFDA remains available for teams with the engineering capacity to build and maintain their own extraction pipeline. This is a viable option for large organizations with dedicated data engineering teams, but it is not practical for most application developers who need interaction checking as one feature among many.

Whatever path you choose, the lesson from 2024-2026 is clear: do not build critical clinical safety features on top of free services without understanding who pays for the infrastructure and whether that funding model is sustainable. The next free API shutdown should not be a surprise.

This information is derived from FDA Structured Product Labeling and is provided for informational purposes only. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.